Table 1.
Demographic and clinical data of the relapsing–remitting multiple sclerosis patients.
| Patients | Gender/ Age |
BMI | Ethnicity | Disease Duration | EDSS | MRI | DMT |
|---|---|---|---|---|---|---|---|
| MS01 | F/59 | 23.11 | Caucasian | 21 years | 5.0 | Gd- | IFN-β-1b |
| MS02 | F/62 | 19.65 | Asiatic | 22 years | ND | ND | IFN-β-1b |
| MS03 | F/50 | 23.33 | Afrodescendent | 26 years | ND | ND | AZA |
| MS04 | F/26 | 24.44 | Caucasian | 3.2 years | 4.5 | Gd+ | GA |
| MS05 | F/69 | 23.42 | Caucasian | 7 years | 3.0 | Gd- | GA |
| MS06 | F/45 | 34.41 | Caucasian | 9 years | 3.0 | Gd+ | TER |
| MS07 | F/37 | 26.67 | Caucasian | 7 years | 4.0 | Gd- | IFN-β-1b |
| MS08 | F/33 | 34.42 | Caucasian | 10 years | 3.0 | ND | GA |
| MS09 | F/30 | 22.98 | Caucasian | 6 years | 3.0 | Gd+ | FTY720 |
| MS10 | F/57 | 25.39 | Caucasian | 15 years | ND | ND | FTY720 |
| MS11 | M/44 | 28.40 | Caucasian | 18 years | 4.5 | Gd- | IFN-β-1a |
| MS12 | F/37 | 23.05 | Caucasian | 13 years | ND | ND | GA |
| MS13 | F/50 | 23.22 | Caucasian | 7 years | 3.5 | Gd+ | IFN-β-1a |
| MS14 | F/33 | 28.00 | Caucasian | 3 years | 4.0 | Gd+ | IFN-β-1a |
| MS15 | F/47 | 27.05 | Caucasian | 7 months | 2.5 | Gd+ | IFN-β-1b |
| MS16 | F/49 | 23.82 | Caucasian | 2 years | 4.0 | Gd+ | NAT |
| MS17 | F/56 | 29.41 | Caucasian | 12 years | ND | ND | FTY720 |
| MS18 | M/45 | 29.66 | Caucasian | 7 years | 3.0 | Gd- | IFN-β-1b |
F: Female; M: Male; BMI: Body Mass Index; EDSS: Expanded Disability Status Score; MRI: Magnetic resonance imaging; Gd+: Presence of gadolinium-enhanced brain lesions; ND: not determined; Gd-: Absence of inflammatory active lesions; DMT: Disease-modifying therapy; IFN-β-1b: Interferon-β-1b; AZA: Azathioprine; GA: Glatiramer acetate; TER: Teriflunomide; FTY720: Fingolimod; NAT: Natalizumab.